TRDA
Closed
Entrada Therapeutics Inc
14.8
-0.6 (-3.90%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 15.39
Day's Range: 14.62 - 15.6299
Send
sign up or login to leave a comment!
When Written:
14.5
Entrada Therapeutics Inc is a biotechnology company that focuses on developing innovative therapies for a range of diseases. The company is based in Boston, Massachusetts, and was founded in 2016. Entrada Therapeutics is focused on developing intracellular biologics, which are designed to target specific disease-causing proteins inside cells.
The company's platform technology is based on a proprietary peptide-based delivery system that allows the biologics to cross the cell membrane and reach their intended targets. Entrada Therapeutics is currently developing therapies for a range of diseases, including genetic disorders, neurodegenerative diseases, and cancer.
Entrada Therapeutics has raised over $200 million in funding to date, including a $116 million Series B financing round in 2020. The company has also established partnerships with several pharmaceutical companies, including Roche and Takeda, to develop and commercialize its intracellular biologics.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's platform technology is based on a proprietary peptide-based delivery system that allows the biologics to cross the cell membrane and reach their intended targets. Entrada Therapeutics is currently developing therapies for a range of diseases, including genetic disorders, neurodegenerative diseases, and cancer.
Entrada Therapeutics has raised over $200 million in funding to date, including a $116 million Series B financing round in 2020. The company has also established partnerships with several pharmaceutical companies, including Roche and Takeda, to develop and commercialize its intracellular biologics.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!